Table 1. Baseline demographic and clinical characteristics of the patients.
| Characteristics | Placebo (n = 25) | Autologous total IgG (n = 26) | |
|---|---|---|---|
| Age (yr) | 26.8 (6.1) | 24.5 (6.0) | |
| Male sex | 19 (76.0) | 18 (69.2) | |
| Body mass index (kg/m2) | 23.7 (4.4) | 23.1 (3.9) | |
| Duration of disease (yr) | 21.0 (8.5) | 19.9 (8.0) | |
| IGA score | |||
| 3 (moderate) | 5 (20.0) | 2 (7.7) | |
| 4 (severe) | 15 (60.0) | 19 (73.1) | |
| 5 (very severe) | 5 (20.0) | 5 (19.2) | |
| SCORAD score | 77.5 (11.7) | 79.4 (8.7) | |
| Body surface area affected (%) | 61.4 (14.7) | 64.0 (14.8) | |
| EASI score | 37.3 (12.3) | 40.5 (10.9) | |
| DLQI score | 18.2 (7.4) | 17.6 (5.8) | |
| Concomitant atopic diseases | |||
| Asthma | 7 (28.0) | 9 (34.6) | |
| Allergic rhinitis | 18 (72.0) | 21 (80.8) | |
| Allergic conjunctivitis | 8 (32.0) | 8 (30.8) | |
Data are presented as mean (standard deviation) or number (%).
IGA, Investigator's Global Assessment; SCORAD, SCORing Atopic Dermatitis; EASI, Eczema Area and Severity Index; DLQI, Dermatology Life Quality Index; IgG, immunoglobulin G.